| 证券代码 | 股票简称 | 权重 | 最新价 | 涨跌幅 | 总市值(亿元) | | 所属行业 | | --- | --- | --- | --- | --- | --- | --- | --- | | sh603259 | 药明康德 | 10.23% | 96.25 | 1.78% | | 2871.87 | 医药生物 | | sh600276 | 恒瑞医药 | 9.85% | 63.06 | -0.03% | | 4185.42 | 医药生物 | | sz300760 | 迈瑞医疗 | 8.23% | 203.94 | 2.17% | | 2472.65 | 医药生物 | | sh688271 | 联影医疗 | 4.25% | 133.99 | 0.90% | | 1104.29 | 医药生物 | | sh600436 | 片仔瘦 | 3.67% | 171.55 | 0.74% | | 1034.99 | 医药生物 | | sz300015 | 爰尔眼科 | 3.39% | 11.40 | 1.97% | | 1063.10 | 医药生物 | | sz300255 | 常山药业 | 2.91% | ...

据工商信息显示， 迈瑞医疗 于2025 年12月31日成立全资子公司济南迈瑞科技有限公司，注册资本2000万元 ，注册地位于济南精准医学产业园，法定代 表人为 迈瑞医疗中国区生命信息与支持事业部总经理 席彬 。 公司经营范围覆盖技术服务、仪器仪表制造、第一类医疗器械生产与销售，并取得第二类、第三类医疗器械生产相关许可。 # 放入迈瑞体系 中 看：一个"结构性补充节点" 长期以来，迈瑞通过多子公司、多节点的方式支撑其全球与国内业务运转。公开资料显示， 其业务覆盖全球190余个国家和地区 ，在海外与国内均设有数 量可观的子公司与分支机构，承担的角色并不局限于销售， 而是根据区域与业务需要，分布在制造、服务、本地运营及细分业务拓展等不同环节 。 在这一体系中，济南迈瑞科技并非孤立存在。由中国区生命信息与支持事业部负责人席彬直接担任法人， 叠加 "制造 + 技术服务 + 进出口" 的经营范围配 置，使其更接近一个具备完整产业职能预期的区域节点，而非轻量化的贸易或壳公司 。这一安排，也与迈瑞过往在不同城市通过实体节点完善区域协同能 力的路径保持一致。 # 区域选择的含义：为后续协同预留空间 # 结语 总体来看，济南迈瑞 ...

图：创业板50指数四大赛道 创业板50指数：追"光"识"新"更掘"金"。横向对比来看，创业板50指数的光模块含量、新能源光伏含量 以及金融科技含量优于创业板指以及主流宽基指数。 创业板50ETF（159949）：汇聚创业板优势领域的成长白马，聚焦于科技成长属性的龙头企业。当前估 值41.83倍，近十年43.14%分位（数据来源：Wind，截至2025-12-31）。 创业板50指数（399673.SZ）权重行业观点： 行情回顾及主要观点： 2025年A股市场表现突出，主要指数全面上扬，成长风格领跑全市场：沪深300涨17.66%，中证500涨 30.39%，中证1000涨27.49%，创业板50涨57.45%，科创50涨35.92%。2025年的A股行情主要由流动性 宽松与主题轮动主导，2026年市场或将进入"业绩验证期"。建议把握政策驱动、盈利修复与景气回升方 向，重点关注科技成长与高端制造板块，如2025年涨幅达57.45%的创业板50指数（同期跑赢创业板指 7.88%）。（数据来源：Wind，截至2025.12.31） 创业板为主要"三创（创新、创造、创意）四新（新技术、新产业、新业态、新模式）"的成长 ...

Group 1 - The medical ETF (512170) opened high on January 6, rising over 1% and reaching a 20-day high, with real-time transaction volume exceeding 350 million yuan. The ETF recorded a daily increase of over 5%, marking five consecutive days of gains [1][5] - Brain-computer interface stocks, including Sanbo Brain Science and Meihua Medical, both hit the 20% daily limit up, achieving two consecutive boards. Conversely, the CXO sector saw a pullback, with Tigermed falling over 1% [1][5] Group 2 - On January 5, 2026, Elon Musk announced that Neuralink plans to start large-scale production of brain-computer interface devices, advancing the commercialization of the technology. Concurrently, the National Medical Products Administration held a meeting to expedite the review and approval of related medical devices [3][6] - According to CITIC Securities, China's brain-computer interface technology is relatively advanced globally, with potential to cultivate leading companies in the sector. This could enhance the valuations of related listed companies in the secondary market and stimulate financing in the primary market, creating a synergy between capital and industry development [7] - Zhongtai Securities noted that the pharmaceutical sector is expected to rebound in 2025 after four consecutive years of decline, driven by the realization of innovative drug export logic and industry recovery post-policy reform. Certain areas of the medical device sector may also see a reversal of difficulties [7]

Group 1 - In the past five trading days, a total of 188 companies were investigated by institutions, with a significant focus on companies like Mindray Medical, CITIC Securities, and Entropy Technology [1] - Among the companies investigated, 57 received attention from more than 20 institutions, with Mindray Medical being the most popular, attracting 205 institutions [1] - The types of institutions involved in the investigations included 171 securities companies, 140 fund companies, and 92 private equity firms, indicating a strong interest from the securities sector [1] Group 2 - In terms of capital inflow, 24 stocks that were investigated by more than 20 institutions saw net capital inflows, with CITIC Securities receiving the highest net inflow of 669 million yuan [1] - Other notable companies with significant net inflows included Zhongke Jiangnan and Entropy Technology, with net inflows of 280 million yuan and 259 million yuan, respectively [1] - The stocks that experienced price increases included Haoshi Electromechanical, Entropy Technology, and Zhongke Jiangnan, with respective gains of 39.71%, 34.81%, and 30.25% [2] Group 3 - The most frequently investigated company was Entropy Technology, which was surveyed three times by institutions, while companies like Jiuli Special Materials and Aidi Tech were surveyed twice [1] - The investigation data also highlighted that 41 stocks among those investigated saw price increases, while 16 experienced declines, with the largest drop being 12.17% for Shenghui Integration [2] - A detailed list of companies investigated included Mindray Medical, CITIC Securities, and Entropy Technology, along with their respective closing prices and percentage changes [2][3]

机构持仓方面，截止2025年9月30日，迈瑞医疗十大流通股东中，香港中央结算有限公司位居第三大流 通股东，持股1.17亿股，相比上期减少1473.63万股。易方达创业板ETF（159915）位居第五大流通股 东，持股1169.35万股，相比上期减少195.91万股。华泰柏瑞沪深300ETF（510300）位居第六大流通股 东，持股1033.58万股，相比上期减少48.07万股。华宝中证医疗ETF（512170）位居第七大流通股东， 持股947.20万股，相比上期减少154.04万股。易方达沪深300医药ETF（512010）位居第九大流通股东， 持股759.59万股，相比上期减少237.30万股。景顺长城新兴成长混合A（260108）位居第十大流通股 东，持股748.00万股，相比上期减少52.00万股。易方达沪深300ETF（510310）退出十大流通股东之 列。 责任编辑：小浪快报 资料显示，深圳迈瑞生物医疗电子股份有限公司位于广东省深圳市南山区高新技术产业园区科技南十二 路迈瑞大厦1-4层,香港湾仔皇后大道东183号合和中心46楼，成立日期1999年1月25日，上市日期2018年 10月16日，公司主营 ...

风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 创业50ETF（159682）业绩比较基准为创业板50指数收益率，管理人为景顺长城基金管理有限公司，基 金经理为汪洋、张晓南，成立（2022-12-23）以来回报为47.75%，近一个月回报为5.23%。 来源：新浪基金∞工作室 1月5日，截止午间收盘，创业50ETF（159682）涨1.90%，报1.505元，成交额1.95亿元。创业50ETF （159682）重仓股方面，宁德时代截止午盘涨1.68%，中际旭创涨1.97%，东方财富涨1.81%，新易盛跌 0.51%，阳光电源涨0.76%，胜宏科技涨2.43%，汇川技术涨4.19%，迈瑞医疗涨4.56%，亿纬锂能涨 4.06%，同花顺涨2.79%。 ...

Group 1 - The A-share medical device sector experienced a significant increase, with the industry index rising by 5.64% on January 5, 2025, and over 60 billion yuan of net inflow from major funds into the sector [1] - The National Medical Products Administration (NMPA) announced adjustments to the management categories of 31 types of medical devices, introducing new categories and refining existing classifications to better align with technological advancements and regulatory needs [1] - The adjustments include the addition of innovative medical devices such as biodegradable magnesium metal clips and tendon repair patches, while also simplifying regulations for low-risk products like manual wheelchairs [1] Group 2 - Recent favorable policies have emerged for the medical device industry, including the NMPA's initiatives to optimize lifecycle regulation and prioritize the approval of high-end medical devices, which aim to accelerate the registration process and market entry [2] - The medical device industry is experiencing growth driven by policy support and market demand, leading to trends such as industry consolidation, increased market concentration, and ongoing investment in research and development [2] - China's medical device export volume continues to grow, with a total export value of 24.1 billion USD in the first half of 2025, reflecting a 5% increase compared to the same period in 2024 [2] Group 3 - Century Securities noted that domestic medical device manufacturers have gained significant market share following extensive centralized procurement, which is expected to benefit from scale effects and export policies [3] - Among the 133 listed companies in the A-share medical device sector, over 70% of those disclosing overseas revenue reported year-on-year growth, with six companies exceeding 1 billion yuan in overseas revenue in the first half of 2025 [3] - Mindray Medical's overseas revenue has consistently increased from 2.615 billion yuan in 2014 to 16.434 billion yuan in 2024, with international revenue expected to account for approximately 50% of total revenue in the first half of 2025 [3] Group 4 - Medical device companies are increasingly focusing on research and development, with 67 companies reporting R&D expenses exceeding 20% of their operating income, indicating a strong commitment to innovation within the sector [4] - Companies like Zhijiang Biology are making significant advancements in core technologies, including nanomagnetic beads and membrane materials, contributing to progress in cutting-edge areas such as membrane technology and organ-on-a-chip systems [5]

2026 年 A 股港股医疗器械和脑机接口重点推荐电话会 20260105 摘要 医疗设备板块 2025 年招标改善，龙头公司如联影、迈瑞等预计 2026 年收入稳定增长或提速，新一期设备更新项目将在 2025 年三季度落地， 明年业绩增速或前低后高。 高值耗材板块受集采政策优化影响，估值和业绩有望恢复，但不同公司 业绩拐点出现时间可能不同。电生理赛道受集采政策优化影响显著，惠 泰医疗估值性价比凸显，北京市发布电生理耗材集采价格公告，惠泰微 电脉冲消融导管产品报价相对较好。 IVD 板块受集采影响预计 2026 年减弱，看好海外业务占比高且增长迅 速的公司，如迈瑞医疗、新产业和联影，通过产品竞争力提升及海外渠 道建设，推动国内医疗器械产品走向国际市场。 迈瑞医疗处于长周期拐点，过去几个季度收入同比增速转正，有望进一 步提升，预计稳健增长背景下实现估值重塑。长期来看，公司已布局数 字化流水线及国际化战略，业务结构从以设备为主转向 IVD 及其他流水 线业务为主，海外市场占比将从当前 40%多提高到接近 60%。 Q&A 2026 年，医疗器械板块预计将迎来估值和业绩的双重修复。自 2020 年以来， 该板块经历 ...

今日（1.5），脑机接口概念股爆发，全市场费率最低档的医疗器械ETF基金(159797)大涨超5%，四连 阴后巨幅反弹！资金面上，医疗器械ETF基金(159797)盘中再获600万份净申购，近10日更是有7日净流 入，累计"吸金"超3000万元！ 医疗器械ETF基金(159797)标的指数成分股多数飘红：乐普医疗20CM涨停，联影医疗、惠泰医疗涨超 4%，迈瑞医疗、新产业涨超3%，鱼跃医疗、爱美客、英科医疗涨超2%。 | 库号 | 代码 | | | | | | --- | --- | --- | --- | --- | --- | | 1 | 300760 | 迈瑞医疗 | 15.26% | 3.95% | 24.60亿 | | 2 | 688271 | 联影医疗 | 8.59% | 4.31% | 7.81亿 | | 3 | 688617 | 重损医疗 | 3.25% | 4.94% | 2.01亿 | | র্ম | 002223 | 色跃医疗 | 3.06% | 2.09% | 3.72 Z | | 5 | 300832 | 新产业 | 3.01% | 3.57% | 1.56亿 | | 6 | 300 ...